NCT06969586Enrolling by invitation
The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy
The Effect of Topical Rho-kinase (ROCK) Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy (FECD)
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
The goal of this study is to learn if topical ROCK inhibitors protect endothelial corneal cells in patients with glaucoma and Fuchs endothelial corneal dystrophy after cataract surgery. The main question it aims to answer is: do topical ROCK inhibitors decrease the loss of corneal endothelial cells after cataract surgery? Researchers will compare topical ROCK inhibitor to a placebo (a look-alike substance that contains no drug) Participants will: Take topical ROCK inhibitor or a placebo every day for 4 weeks after cataract surgery and visit the clinic for checkups and tests.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 27 Apr 2025
- Start date
- 1 Apr 2025
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- University Hospital Dubrava
- Diseases
- Glaucoma
- NCT number
- NCT06969586
What you commit to
- Study type: Observational
- Planned participants: 50
- From 1 Apr 2025 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous ocular trauma or intraocular surgery
Other illness
- other anterior segment pathology (pseudoexfoliation syndrome, corneal opacities);
Other
- ocular surface inflammation;
- intraoperative complications (posterior capsular rupture, vitreous loss, IOL not implanted in the capsular bag);
Who the study is looking for
- age between 40 and 90 years;
- diagnosis of FECD and glaucoma;
- cataract grade II nuclear/cortical or posterior subcapsular (Lens Opacity Classification System III \[LOCS III\].
Age in the registry: 40 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Dubrava Coordinator of this site? Confirm its status | Zagreb | Croatia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.